Grant
FSHD Global Announces Funding for miRecule 2nd generation therapy
A Sydney research foundation has put funding into miRecule's next-generation therapy for facioscapulohumeral muscular dystrophy, which targets two disease mechanisms; the biotech hopes to run early trials in Australia.